Abstract: The present invention relates to an improved multi-step method for preparing an extract from ginkgo biloba having a reduced content of 4?-O-methyl pyridoxine and/or biflavones, wherein the depletion is carried out by filtration over an adsorber resin and/or an ion exchanger and the substances to be removed are retained on the resin. The invention further relates to an extract from ginkgo biloba having a reduced content of 4?-O-methyl pyridoxine and/or biflavones, which is obtainable by the method according to the present invention, as well as to its use.

Abstract: A nucleic acid molecule or construct alone or with a promoter suitable for expression control is contemplated that codes for a KLH1 haemocyanin, a haemocyanin domain or a fragment thereof with the immunological properties of at least one domain of haemocyanin, and comprises at least one intron sequence, as well as haemocyanin fusion proteins. The construct can also comprise a nucleic acid sequence that codes for an antigen. Host cells are also contemplated that contain the nucleic acid molecule or construct and a recombinant expression product thereof. The invention further relates to a pharmaceutical composition that comprises the expression product and antibodies obtainable by immunization of an animal therewith, as well as the use of antibodies in screening methods for the identification of tumors.

Abstract: A microbicidally coated article, especially a container, having on at least part of it a coating comprising an organically modified inorganic matrix comprising silver colloids which is obtainable by application of a coating composition comprising a) a hydrolysate or condensate based on at least one hydrolysable silane with at least one non-hydrolysable substituent and b) a silver compound to the surface of the article and treatment with heat and/or radiation to form the silver colloid coating. Articles coated in accordance with the invention are therefore particularly suitable for purposes of disinfection, preservation, cosmetic, pharmaceutical or medical purposes. Articles from the pharmaceutical or medical sector, especially containers for pharmaceuticals or articles or components which come into contact with the human body and are required to be free from germs, are preferred fields of application.

Abstract: A nucleic acid molecule or construct alone or with a promoter suitable for expression control is contemplated that codes for a HLH2 haemocyanin polypeptide and comprises at least one intron sequence, as well as haemocyanin fusion proteins. The construct further can comprise a nucleic acid sequence that codes for an antigen. Host cells are also contemplated that contain the nucleic acid molecules or construct and recombinant expression product thereof. The invention further relates to a pharmaceutical composition that comprises the expression product of that nucleic acid and antibodies obtainable by immunization of an animal therewith, as well as use of the antibodies in screening methods for the identification of tumors.

Abstract: Oral dosage form for food and food supplement as well as dietetics comprising polyunsaturated acids in a xylose-hardened gelatine capsule with a retarded release time.

Abstract: The present invention relates to a composition with trace elements for nutrition. The composition is characterised by an increased content of selenium and/or zinc as a trace element.

Abstract: A fluid dispenser for germ-free fluid is described incorporating at least one material being capable of interacting via an oligodynamically active substance. The dispenser includes a metering pump and inlet and outlet valves. The fluid coming into contact with at least one oligodynamically active substance is present in the region of the outlet valve, of the inlet thereto and/or the outlet therefrom.

Abstract: A swellable intermediate layer that includes a swellable material selected from the group of starch, starch derivatives such as pregelatinised starch, sodium carboxyethyl starch, sodium starch gycolate, cellulose, cellulose ethers such as HPMC, HPC, HEC MC, sodium carboxymethyl cellulose, carrageenans, aginates, pectins, xanthanes and their derivatives, guar gum, tragacanth, polyvinyl pyrrolidones and mixtures thereof, in a delayed-release, solid pharmaceutical formulation for peroral use. The formulation has a substrate containing an active substance, the swellable intermediate layer and a retarding coating layer for the adjustment of a release profile for the active substance which essentially permits complete release near the end.

Abstract: The present invention relates to the use of extracts from Cimicifuga racemosa, and of tectorigenin as an estrogen-type, organoselective medicament for the selective treatment and/or prophylaxis of cardiovascular diseases, atherosclerosis, osteoporosis and climacteric disorders, e.g. for preventing or alleviating hot flushes. Uterotrophic effects are practically not observed.

Abstract: The present invention relates to a method for preparing an extract from ginkgo biloba having a reduced content of nonpolar plant ingredients and nonpolar impurities due to environmental influences compared to the initial extract, the method being characterized by the following method steps: (a) preparing an aqueous-ketonic or aqueous-alcoholic solution of an initial ginkgo biloba extract and applying the solution to an adsorber resin, (b) eluting the adsorber resin with an aqueous C3-C6 ketone or an aqueous C1-C3 alcohol and (c) optionally concentrating and drying the extract solution thus obtained to the dry extract. The invention further relates to an extract (liquid extract or spissum extract as well as dry extract) from ginkgo biloba having a reduced content of nonpolar plant ingredients and nonpolar impurities due to environmental influences compared to the initial extract, which is obtainable by the method of the present invention.

Abstract: A method and device for identifying, testing or clearing a prefilled medicinal syringe in which the syringe is inserted into the test device which reads coding on the syringe and has a display as to whether the syringe is appropriate or not.

Abstract: The present invention relates to an improved multi-step method for preparing an extract from Ginkgo biloba having a reduced content of polycyclic aromatic hydrocarbons. The invention further relates to an extract from Ginkgo biloba having a reduced content of polycyclic aromatic hydrocarbons which is obtainable by the method according to the present invention, as well to its use.

Abstract: The present invention relates to an improved multi-step method for preparing an extract from ginkgo biloba having a reduced content of 4?-O-methyl pyridoxine and/or biflavones, wherein the depletion is carried out by filtration over an adsorber resin and/or an ion exchanger and the substances to be removed are retained on the resin. The invention further relates to an extract from ginkgo biloba having a reduced content of 4?-O-methyl pyridoxine and/or biflavones, which is obtainable by the method according to the present invention, as well as to its use.

Abstract: The present invention relates to a method for preparing an extract from Ginkgo biloba having a reduced content of 4?-O-methyl pyridoxine and/or biflavones compared to the original extract. The invention further relates to extracts from Ginkgo biloba having a reduced content of 4?-O-methyl pyridoxine and/or biflavones compared to the original extract, which is obtainable by the method according to the present invention, as well as to their use.

Abstract: The present invention relates to the use of rutin and isorhamnetin for the treatment of episodes of depression and depressive diseases as well as in case of other affective disorders and preliminary stages thereof.

Abstract: The invention relates to a method for purifying at least one enzyme obtained in an excess fermentation of Clostridium histolyticum. It is provided for that the enzymes of the excess fermentation are separated by a multistage chromatography method by exclusively using chromatography materials on styrene/divinyl-benzene base and/or on base of in particular ceramic hydroxylapatite.

Abstract: A prefilled medical syringe includes a syringe barrel. A syringe plunger is disposed in the barrel and displaceable by means of a plunger rod. An end plug closes off a cannula side of the syringe barrel. The plug is provided with a through-channel closed off by a membrane. A finger support is disposed at the end of the syringe barrel opposite the end plug and provided with a through-opening for the plunger rod. A thread system cooperates with the plunger rod and the finger support. The thread system includes a thread sleeve detachably connected with the finger support. The thread sleeve is provided with an inner thread that cooperates with an outer thread on the plunger rod.

Abstract: Prefilled syringes are made by displacing a succession of syringes along a conveyor path from a supply station successively through a marking station, a filling station, and to a downstream packing station. Each of the syringes is filled with a predetermined dose of a medicament in the filling station. The syringes are marked in the marking station with machine-readable data identifying the medicament to be put in the empty syringe at the filling station. The syringes are scanned downstream of the marking station and any syringe whose data is not readable is then removed from the conveyor path, as is any syringe whose data does not correspond to the medicament filled into the syringe at the filling station.

Abstract: The invention concerns the use of papaverine-like vasodilator for the production of a pharmaceutical composition for the treatment of ophthalmological dysfunctions which are linked to circulatory disturbances of the eye or which are to be attributed to circulatory disturbances of the eye, wherein the pharmaceutical composition is to be applied topically to the eye. The invention further concerns a pharmaceutical composition which includes papaverine-like vasodilator and pharmacologically compatible viscosity regulator.

Abstract: A fluid dispenser for germ-free fluid is described incorporating at least one material being capable of interacting via an oligodynamically active substance. The dispenser includes a metering pump and inlet and outlet valves. The fluid coming into contact with at least one oligodynamically active substance is present in the region of the outlet valve, of the inlet thereto and/or the outlet therefrom.